Vivet Therapeutics’ lead program, VTX-801 for Wilson Disease, was highlighted during Pfizer’s Investor Day September 15th 2020.
PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration
Vivet Therapeutics, a privately held gene therapy biotech company
Vivet is very happy to share the March 2020
Vivet Therapeutics' CEO, Jean-Philippe Combal
Vivet Announces Publication in Nature Communications of Preclinical Data from VTX-803
Jean-Philippe Combal, Vivet Therapeutics' CEO, and Thomas Daniel, BD Director, will be hosting 1x1 meetings during
Vivet Therapeutics CEO, Jean-Philippe Combal
Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO
Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO & Head of the Gene Therapy